×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Failed Phase III For NeoCart May Still Fly With US FDA, Histogenics Argues
Pink Sheet
Failed Phase III For NeoCart May Still Fly With US FDA, Histogenics Argues · Deal Watch: Gilead To Use Insitro's AI/Functional Genomics Tech For NASH Targets.
7 months ago
Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company ...
Business Wire
Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company.
55 months ago
Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company ...
Ocugen
Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene...
61 months ago
NeoCart's Revival Continues as FDA Approves Ocugen's Phase III Trial Design (Updated)
BioSpace
Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.
16 months ago
425
SEC.gov
TIME IS SHORT AND YOUR VOTE IMPORTANT! You can vote your shares TODAY via telephone or by Internet. Please follow the easy instructions on...
56 months ago
Histogenics plunges on missed endpoint in NeoCart trial
MassDevice
Waltham, Mass.-based Histogenics said NeoCart, which is designed to repair knee cartilage damage using cells harvested from the surface of...
68 months ago
Histogenics Completes Enrollment for Phase 3 Clinical Trial of Neocart® to Treat Knee Cartilage Damage
GlobeNewswire
NeoCart is a cartilage-like, tissue engineered implant created from a patient's own cartilage cells. The patient's cells are multiplied in...
82 months ago
Ocugen, Histogenics merge to form eye disease specialist
Pharmaphorum
Ocugen says that OCU400 differs from highly-specific single-gene therapies, such as Spark Therapeutics' Luxturna (voretigene neparvovec) which...
61 months ago
Peter Greenleaf is the new CEO of Histogenics
Boston.com
Histogenics Corp., a regenerative medicine company based in Waltham, said Monday that it has appointed Peter Greenleaf to be its new chief...
131 months ago
Histogenics (HSGX) Stock Price, News & Analysis
MarketBeat
About Histogenics Stock (NASDAQ:HSGX). Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored...
93 months ago